Prominent biotech investor RA Capital Management has liquidated its entire position in Sarepta Therapeutics (SRPT), according to its latest quarterly disclosure. The firm sold all 3.90 million shares it held, which were previously valued at approximately $84.92 million. This represents a significant portfolio move by the specialist fund.
As with all 13F filings, this report, filed on August 14, 2026, is retrospective and reflects trading activity that occurred during the second quarter ending June 30, 2026. The exit took place during a quarter in which Sarepta announced a CEO transition and later reported mixed financial results with narrowed revenue guidance for the year. [1, 4]